News & Events about Mannkind Corp.
Globe Newswire
2 months ago
Conference Call to Begin Today at 9:00 a.m. (ET)3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 20213Q 2022 Royalties from Tyvaso DPI of $6.2 million3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 08, 2022 (GLOBE ...
Simply Wall St
4 months ago
A look at the shareholders of MannKind Corporation ( NASDAQ:MNKD ) can tell us which group is most powerful. And the...
Globe Newswire
7 months ago
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and ...
Principal Financial Group Inc. lessened its holdings in shares of MannKind Co. (NASDAQ:MNKD Get Rating) by 11.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 338,126 shares of the biopharmaceutical companys stock after ...
Ticker Report
8 months ago
Citigroup Inc. raised its stake in MannKind Co. (NASDAQ:MNKD Get Rating) by 88.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 671,215 shares of the biopharmaceutical companys stock after buying an additional 315,097 shares during the quarter. Citigroup Inc.s...